Search
ECOG E4512 (NCT02201992) **SUSPENDED** – Must have Consented to ALCHEMIST A151216 Trial
This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Please Note:
Must have Consented to ALCHEMIST A151216 Trial
Available Sites
- Missouri Baptist Medical Center
- Missouri Baptist Outpatient Center – Sunset Hills
- Missouri Baptist Sullivan Hospital
- Sainte Genevieve County Memorial Hospital
- Parkland Health Center - Farmington
Contact Person(s)
- Patricia Kulla, 314-996-4617
View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.
